ClinicalTrials.gg
CompletedNCT02175680Updated Apr 14, 2023Results posted

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

A Phase 2 interventional study of PRO 140 and Historical data in HIV and Human Immunodeficiency Virus, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.

Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment, and one week overlap at the end of the treatment in subjects who do not experience virologic failure.

Read the detailed description

This study is a Phase 2b, multi-center study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in patients who are stable on combination antiretroviral therapy.

Patient enrollment will be staggered in this study to facilitate adequate safety monitoring. A lead cohort will include 12 subjects. Enrollment of additional 28 subjects will not be initiated until it is approved by the independent Data Monitoring Committee (DMC).

Consenting patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be up to 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience Virologic Failure.

PRO 140 will be administered as a 350 mg subcutaneous injection weekly for up to 14 weeks. Study participants will be monitored for viral rebound on a weekly basis following initiation of PRO 140 monotherapy and will re-initiate their previous antiretroviral regimen if plasma HIV-1 RNA levels rise above 400 copies/ml on two consecutive blood draws at least 3 days apart.

The study will have three phases: Screening Phase, Treatment Phase and Follow-up Phase.

The primary objective is to assess efficacy of PRO 140 monotherapy for the maintenance of viral suppression following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.

The secondary objective of the trial is to assess the clinical safety and tolerability parameters following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.

02

Conditions studied

  • HIV
  • Human Immunodeficiency Virus

Browse trials for

Keywords

  • HIV-1
  • HIV
  • Treatment Substitution
  • PRO 140
  • PRO140
  • CytoDyn
  • Amarex
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 43 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age ≥18 years
  2. Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay
  3. On stable antiretroviral therapy for last 12 months
  4. Subject has two or more potential alternative antiretroviral regimen options to consider.
  5. No documented detectable viral loads (-1 RNA \<50 copies/ml) within the last 12 months prior to Screening Visit
  6. Nadir of >200 cells/mm3

Exclusion criteria

Exclusion Criteria:

  1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay at the Screening Visit
  2. infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)
  3. Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition
  4. Prior use of any entry, attachment, CCR5 co-receptor, or fusion inhibitor, including PRO 140.
  5. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    PRO 140

    PRO 140 350mg weekly SQ injection.

    Drug: PRO 140 · Other: Historical data

Interventions

  • CCR5 Antagonist

    Also known as: PRO 140 350mg

  • OtherHistorical data

    Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).

06

What researchers measure

Primary outcomes

  1. Time to Virologic Failure After Initiating PRO 140 Monotherapy.

    Time to virologic failure after initiating PRO 140 monotherapy. Virologic failure was defined as two (2) consecutive HIV-1 RNA levels of ≥ 400 copies/mL.

    Time frame: From initiation of PRO 140 monotherapy through week 14 or virological failure

Secondary outcomes

  1. Proportion of Subjects With Virologic Failure

    Proportion of Participants with Virologic Failure after initiating PRO 140 monotherapy at or prior to Week 14.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  2. Mean Change From Baseline in Viral Load

    Mean change in Viral Load (HIV-1 RNA levels - log 10 copies/ml)), at each visit within the 14-week treatment phase.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  3. Change in Viral Load at the Last Virologic Failure Visit.

    Mean Change from Baseline in viral load at the last virologic failure visit from Week 1 to Week 14. VF can occur at any time during the treatment phase from week 1 to week 14. Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

    Time frame: From baseline to virologic failure visit (VF). VF can occur at any time from Week 1 to Week 14.

  4. Mean Change in CD4 Cell Count by Visit

    Mean change in CD4 cell count, at each visit within the 14-week treatment phase

    Time frame: From baseline (week 2) through week 14

  5. Mean Change in CD4 Cell Count

    Change from baseline in CD4 cell count, within the 14-week treatment phase

    Time frame: From baseline (week 2) to last visit

  6. Q1 QOL Health Status

    Quality of Life Q1 Current General Health Status, is collected from base line to virologic failure (VF can occur at any time from any time during the treatment phase from week 1 to week 14). Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

    Time frame: From baseline to virologic failure (VF occurring at any time from Week 1 to Week 12 or virologic failure which ever comes first)

  7. Q2 QOL Current State of Health

    Subjects will rate their current state of health via Visual Analog Scale (VAS) using the line as a guide, with 0 as death or worst possible health and 100 as perfect or best possible health. A higher score indicates best outcome. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

    Time frame: From week 1 through treatment weeks 4, 8, 12 or VF visit

Other outcomes

  1. Injection Site Reaction - Pain (Site 1)

    Injection site reaction pain assessment @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  2. Injection Site Reaction - Pain (Site 2)

    Injection site reaction pain assessment @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  3. Injection Site Reaction - Injection Site Status (Site 1)

    Summary of injection site reaction assessment - Injection site status @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  4. Injection SIte Reaction - Injection Site Status (Site 2)

    Summary of injection site reaction assessment - Injection site status @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  5. Injection Site Reaction - Pruritus With Injection (Site 1)

    Summary of injection site reaction assessment - Pruritus with injection @Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  6. Injection Site Reaction - Pruritus With Injection (Site 2)

    Summary of injection site reaction assessment - Pruritus with injection @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week14

  7. Injection Site Reaction - Bleeding Site 1

    Summary of injection site reaction assessment - bleeding @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  8. Injection Site Reaction - Bleeding - Site 2

    Summary of injection site reaction assessment - bleeding @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week14

  9. Injection Site Reaction - Drug Absorption - Site 1

    Summary of injection site reaction assessment - drug absorption @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week14

  10. Injection Site Reaction - Drug Absorption - Site 2

    Summary of injection site reaction assessment - drug absorption @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  11. Injection Site Reaction - Pain Post Injection - Site 1

    Summary of injection site pain assessment (VAS) post injection mean change from baseline. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. Higher score is worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  12. Injection Site Reaction - Pain Post Injection - Site 2

    Summary of injection site pain assessment (VAS) post injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. A higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From initiation of PRO 140 monotherapy through week 14

  13. Injection Site Reaction - Pain Pre Injection - Site 1

    Summary of injection site pain assessment (VAS) pre injection @ Site 1 Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From week 2 through week 14

  14. Injection Site Reaction - Pain Pre Injection - Site 2

    Summary of injection site pain assessment (VAS) pre injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

    Time frame: From week 2 through week 14

  15. Pro 140 Concentration

    Summary of Pro 140 Concentration. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL).

    Time frame: At week 4, week 8, week 12 and viral failure visits

07

Results

Posted Apr 14, 2023

Participant flow

Participant flow — Overall Study
MilestonePRO 140 350 mg Weekly SQ Injection
Started43
Completed41
Not completed2
Withdrew: Non-compliance1
Withdrew: Other non-medical reason1

Outcome measures

PrimaryTime to Virologic Failure After Initiating PRO 140 Monotherapy.

Time to virologic failure after initiating PRO 140 monotherapy. Virologic failure was defined as two (2) consecutive HIV-1 RNA levels of ≥ 400 copies/mL.

Time frame:
From initiation of PRO 140 monotherapy through week 14 or virological failure
Reported as:
Mean · days
Time to Virologic Failure After Initiating PRO 140 Monotherapy.
daysPRO 140 350 mg
Time to Virologic Failure After Initiating PRO 140 Monotherapy.70.71 ± 23.14
Statistical analysis
  • PRO 140 350 mg · Wilcoxon Rank Sum · p = <0.0001The time to Virologic Failure for the subjects treated with PRO 140 monotherapy was compared to historical data.
SecondaryProportion of Subjects With Virologic Failure

Proportion of Participants with Virologic Failure after initiating PRO 140 monotherapy at or prior to Week 14.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Number · poportion of subjects
Proportion of Subjects With Virologic Failure
poportion of subjectsPRO 140 350 mg
Proportion of Subjects With Virologic Failure0.439
SecondaryMean Change From Baseline in Viral Load

Mean change in Viral Load (HIV-1 RNA levels - log 10 copies/ml)), at each visit within the 14-week treatment phase.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Mean · log 10 copies/mL
Mean Change From Baseline in Viral Load
log 10 copies/mLPRO 140
T2 (Week 2)0.10 ± 0.71
T3 (Week 3)0.01 ± 0.74
T4 (Week 4)-0.13 ± 0.74
T5 (Week 5)-0.25 ± 1.04
T6 (Week 6)-0.76 ± 1.39
T7 (Week 7)-0.88 ± 1.53
T8 (Week 8)-0.72 ± 1.37
T9 (Week 9)-0.84 ± 1.37
T10 (Week 10)-0.71 ± 1.36
T11 (Week 11)-0.81 ± 1.37
T12 (Week 12)-0.91 ± 1.50
T13 (Week 13)-0.44 ± 1.12
T14 (Week 14)-0.37 ± 1.09
SecondaryChange in Viral Load at the Last Virologic Failure Visit.

Mean Change from Baseline in viral load at the last virologic failure visit from Week 1 to Week 14. VF can occur at any time during the treatment phase from week 1 to week 14. Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

Time frame:
From baseline to virologic failure visit (VF). VF can occur at any time from Week 1 to Week 14.
Reported as:
Mean · log 10 copies/ml
Change in Viral Load at the Last Virologic Failure Visit.
log 10 copies/mlPRO 140 350 mg Weekly SQ Injection
Change in Viral Load at the Last Virologic Failure Visit.-1.78 ± 1.93
SecondaryMean Change in CD4 Cell Count by Visit

Mean change in CD4 cell count, at each visit within the 14-week treatment phase

Time frame:
From baseline (week 2) through week 14
Reported as:
Mean · cells/mm^3
Mean Change in CD4 Cell Count by Visit
cells/mm^3PRO 140
T2 (Week 2)32.05 ± 132.92
T3 (Week 3)-33.14 ± 137.05
T4 (Week 4)-12.78 ± 137.37
T5 (Week 5)33.42 ± 130.88
T6 (Week 6)-3.26 ± 125.78
T7 (Week 7)47.50 ± 190.10
T8 (Week 8)-55.09 ± 157.21
T9 (Week 9)47.25 ± 95.64
T10 (Week 10)-6.82 ± 140.34
T11 (Week 11)-29.83 ± 218.64
T12 (Week 12)16.52 ± 143.91
T13 (Week 13)-0.44 ± 95.54
T14 (Week 14)-59.03 ± 56.50
VF (Viral failure)18.41 ± 113.99
SecondaryMean Change in CD4 Cell Count

Change from baseline in CD4 cell count, within the 14-week treatment phase

Time frame:
From baseline (week 2) to last visit
Reported as:
Mean · cells/mm^3
Mean Change in CD4 Cell Count
cells/mm^3PRO 140
Mean Change in CD4 Cell Count18.97 ± 114.08
SecondaryQ1 QOL Health Status

Quality of Life Q1 Current General Health Status, is collected from base line to virologic failure (VF can occur at any time from any time during the treatment phase from week 1 to week 14). Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

Time frame:
From baseline to virologic failure (VF occurring at any time from Week 1 to Week 12 or virologic failure which ever comes first)
Reported as:
Count of participants · Participants
Q1 QOL Health Status
ParticipantsPRO 140 350 mg
T1 (Week 1) — Poor0
T1 (Week 1) — Fair1
T1 (Week 1) — Good6
T1 (Week 1) — Very Good10
T1 (Week 1) — Excellent13
T1 (Week 1) — Missing11
T4 (Week 4) — Poor0
T4 (Week 4) — Fair1
T4 (Week 4) — Good6
T4 (Week 4) — Very Good11
T4 (Week 4) — Excellent12
T4 (Week 4) — Missing11
T8 (Week 8) — Poor1
T8 (Week 8) — Fair2
T8 (Week 8) — Good6
T8 (Week 8) — Very Good9
T8 (Week 8) — Excellent9
T8 (Week 8) — Missing14
T12 (Week 12) — Poor0
T12 (Week 12) — Fair2
T12 (Week 12) — Good2
T12 (Week 12) — Very Good12
T12 (Week 12) — Excellent5
T12 (Week 12) — Missing20
VF (Virologic Failure) — Poor0
VF (Virologic Failure) — Fair0
VF (Virologic Failure) — Good3
VF (Virologic Failure) — Very Good3
VF (Virologic Failure) — Excellent1
VF (Virologic Failure) — Missing34
SecondaryQ2 QOL Current State of Health

Subjects will rate their current state of health via Visual Analog Scale (VAS) using the line as a guide, with 0 as death or worst possible health and 100 as perfect or best possible health. A higher score indicates best outcome. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)

Time frame:
From week 1 through treatment weeks 4, 8, 12 or VF visit
Reported as:
Mean · score on a scale
Q2 QOL Current State of Health
score on a scalePRO 140 350mg
T1 (Week 1)82.3 ± 16.4
T4 (Week 4)83.8 ± 16.2
T8 (Week 8)80.9 ± 18.0
T12 (Week 12)84.9 ± 17.3
VF (Viral Failure)78.0 ± 15.8
Other pre-specifiedInjection Site Reaction - Pain (Site 1)

Injection site reaction pain assessment @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Pain (Site 1)
ParticipantsPRO 140 350 mg Weekly SQ Injection
T1 (Week 1) — absent43
T1 (Week 1) — present0
T2 (Week 2) — absent43
T2 (Week 2) — present0
T3 (Week 3) — absent43
T3 (Week 3) — present0
T4 (Week 4) — absent43
T4 (Week 4) — present0
T5 (Week 5) — absent43
T5 (Week 5) — present0
T6 (Week 6) — absent43
T6 (Week 6) — present0
T7 (Week 7) — absent41
T7 (Week 7) — present0
T8 (Week 8) — absent36
T8 (Week 8) — present0
T9 (Week 9) — absent33
T9 (Week 9) — present0
T10 (Week 10) — absent29
T10 (Week 10) — present0
T11 (Week 11) — absent29
T11 (Week 11) — present0
T12 (Week 12) — absent27
T12 (Week 12) — present0
T13 (Week 13) — absent22
T13 (Week 13) — present1
T14 (Week 14) — absent6
T14 (Week 14) — present0
Other pre-specifiedInjection Site Reaction - Pain (Site 2)

Injection site reaction pain assessment @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Pain (Site 2)
ParticipantsPRO 140 350mg
T1 (Week 1) — absent43
T1 (Week 1) — present0
T2 (Week 2) — absent43
T2 (Week 2) — present0
T3 ( Week 3) — absent43
T3 ( Week 3) — present0
T4 (Week 4) — absent43
T4 (Week 4) — present0
T5 (Week 5) — absent43
T5 (Week 5) — present0
T6 (Week 6) — absent43
T6 (Week 6) — present0
T7 (Week 7) — absent41
T7 (Week 7) — present0
T8 (Week 8) — absent36
T8 (Week 8) — present0
T9 (Week 9) — absent29
T9 (Week 9) — present0
T10 (Week 10) — absent29
T10 (Week 10) — present0
T11 (Week 11) — absent29
T11 (Week 11) — present0
T12 (Week 12) — absent27
T12 (Week 12) — present0
T13 (Week 13) — absent23
T13 (Week 13) — present0
T14 ( Week 14) — absent6
T14 ( Week 14) — present0
Other pre-specifiedInjection Site Reaction - Injection Site Status (Site 1)

Summary of injection site reaction assessment - Injection site status @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Injection Site Status (Site 1)
ParticipantsPRO 140 350mg
T1 (Week 1) — Normal43
T1 (Week 1) — abnormal0
T2 (Week 2) — Normal43
T2 (Week 2) — abnormal0
T3 (Week 3) — Normal43
T3 (Week 3) — abnormal0
T4 (Week 4) — Normal43
T4 (Week 4) — abnormal0
T5 (Week 5) — Normal43
T5 (Week 5) — abnormal0
T6 (Week 6) — Normal42
T6 (Week 6) — abnormal1
T7 (Week 7) — Normal41
T7 (Week 7) — abnormal0
T8 (Week 8) — Normal36
T8 (Week 8) — abnormal0
T9 (Week 9) — Normal33
T9 (Week 9) — abnormal0
T10 (Week 10) — Normal29
T10 (Week 10) — abnormal0
T11 (Week 11) — Normal29
T11 (Week 11) — abnormal0
T12 (Week 12) — Normal27
T12 (Week 12) — abnormal0
T13 (Week 13) — Normal23
T13 (Week 13) — abnormal0
T14 (Week 14) — Normal6
T14 (Week 14) — abnormal0
Other pre-specifiedInjection SIte Reaction - Injection Site Status (Site 2)

Summary of injection site reaction assessment - Injection site status @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection SIte Reaction - Injection Site Status (Site 2)
ParticipantsPRO 140 350 mg Weekly SQ Injection
T1 (Week 1) — Normal43
T1 (Week 1) — Abnormal0
T2 (Week 2) — Normal43
T2 (Week 2) — Abnormal0
T3 (Week 3) — Normal43
T3 (Week 3) — Abnormal0
T4 (Week 4) — Normal43
T4 (Week 4) — Abnormal0
T5 (Week 5) — Normal43
T5 (Week 5) — Abnormal0
T6 (Week 6) — Normal42
T6 (Week 6) — Abnormal1
T7 (Week 7) — Normal41
T7 (Week 7) — Abnormal0
T8 (Week 8) — Normal36
T8 (Week 8) — Abnormal0
T9 (Week 9) — Normal33
T9 (Week 9) — Abnormal0
T10 (Week 10) — Normal29
T10 (Week 10) — Abnormal0
T11 (Week 11) — Normal29
T11 (Week 11) — Abnormal0
T12 (Week 12) — Normal27
T12 (Week 12) — Abnormal0
T13 (Week 13) — Normal23
T13 (Week 13) — Abnormal0
T14 (Week 14) — Normal6
T14 (Week 14) — Abnormal0
Other pre-specifiedInjection Site Reaction - Pruritus With Injection (Site 1)

Summary of injection site reaction assessment - Pruritus with injection @Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Pruritus With Injection (Site 1)
ParticipantsPRO 140 350mg
T1 (Week 1) — Absent43
T1 (Week 1) — Present0
T2 (Week 2) — Absent42
T2 (Week 2) — Present1
T3 (Week 3) — Absent43
T3 (Week 3) — Present0
T4 (Week 4) — Absent43
T4 (Week 4) — Present0
T5 (Week 5) — Absent43
T5 (Week 5) — Present0
T6 (Week 6) — Absent43
T6 (Week 6) — Present0
T7 (Week 7) — Absent41
T7 (Week 7) — Present0
T8 (Week 8) — Absent36
T8 (Week 8) — Present0
T9 (Week 9) — Absent33
T9 (Week 9) — Present0
T10 (Week 10) — Absent29
T10 (Week 10) — Present0
T11 (Week 11) — Absent29
T11 (Week 11) — Present0
T12 (Week 12) — Absent27
T12 (Week 12) — Present0
T13 (Week 13) — Absent23
T13 (Week 13) — Present0
T14 (Week 14) — Absent6
T14 (Week 14) — Present0
Other pre-specifiedInjection Site Reaction - Pruritus With Injection (Site 2)

Summary of injection site reaction assessment - Pruritus with injection @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week14
Reported as:
Count of participants · Participants
Injection Site Reaction - Pruritus With Injection (Site 2)
ParticipantsPRO 140 350mg
T1 (Week 1) — Absent43
T1 (Week 1) — Present0
T2 (Week 2) — Absent42
T2 (Week 2) — Present1
T3 (Week 3) — Absent43
T3 (Week 3) — Present0
T4 (Week 4) — Absent43
T4 (Week 4) — Present0
T5 (Week 5) — Absent43
T5 (Week 5) — Present0
T6 (Week 6) — Absent43
T6 (Week 6) — Present0
T7 (Week 7) — Absent41
T7 (Week 7) — Present2
T8 (Week 8) — Absent36
T8 (Week 8) — Present0
T9 (Week 9) — Absent33
T9 (Week 9) — Present0
T10 (Week 10) — Absent29
T10 (Week 10) — Present0
T11 (Week 11) — Absent29
T11 (Week 11) — Present0
T12 (Week 12) — Absent27
T12 (Week 12) — Present0
T13 (Week 13) — Absent23
T13 (Week 13) — Present0
T14 (Week 14) — Absent6
T14 (Week 14) — Present0
Other pre-specifiedInjection Site Reaction - Bleeding Site 1

Summary of injection site reaction assessment - bleeding @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Bleeding Site 1
ParticipantsPRO 140 350mg
T1 (Week 1) — Absent43
T1 (Week 1) — Present0
T2 (Week 2) — Absent43
T2 (Week 2) — Present0
T3 (Week 3) — Absent43
T3 (Week 3) — Present0
T4 (Week 4) — Absent43
T4 (Week 4) — Present0
T5 (Week 5) — Absent43
T5 (Week 5) — Present0
T6 (Week 6) — Absent43
T6 (Week 6) — Present0
T7 (Week 7) — Absent41
T7 (Week 7) — Present0
T8 (Week 8) — Absent36
T8 (Week 8) — Present0
T9 (Week 9) — Absent33
T9 (Week 9) — Present0
T10 (Week 10) — Absent29
T10 (Week 10) — Present0
T11 (Week 11) — Absent29
T11 (Week 11) — Present0
T12 (Week 12) — Absent27
T12 (Week 12) — Present0
T13 (Week 13) — Absent23
T13 (Week 13) — Present0
T14 (Week 14) — Absent6
T14 (Week 14) — Present0
Other pre-specifiedInjection Site Reaction - Bleeding - Site 2

Summary of injection site reaction assessment - bleeding @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week14
Reported as:
Count of participants · Participants
Injection Site Reaction - Bleeding - Site 2
ParticipantsPRO 140 350mg
T1 (Week 1) — Absent43
T1 (Week 1) — Present0
T2 (Week 2) — Absent43
T2 (Week 2) — Present0
T3 (Week 3) — Absent43
T3 (Week 3) — Present0
T4 (Week 4) — Absent43
T4 (Week 4) — Present0
T5 (Week 5) — Absent42
T5 (Week 5) — Present0
T6 (Week 6) — Absent42
T6 (Week 6) — Present0
T7 (Week 7) — Absent41
T7 (Week 7) — Present0
T8 (Week 8) — Absent36
T8 (Week 8) — Present0
T9 (Week 9) — Absent33
T9 (Week 9) — Present0
T10 (Week 10) — Absent29
T10 (Week 10) — Present0
T11 (Week 11) — Absent29
T11 (Week 11) — Present0
T12 (Week 12) — Absent26
T12 (Week 12) — Present1
T13 (Week 13) — Absent23
T13 (Week 13) — Present0
T14 (Week 14) — Absent6
T14 (Week 14) — Present0
Other pre-specifiedInjection Site Reaction - Drug Absorption - Site 1

Summary of injection site reaction assessment - drug absorption @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week14
Reported as:
Count of participants · Participants
Injection Site Reaction - Drug Absorption - Site 1
ParticipantsPRO 140 350mg
T1 (Week 1) — Normal43
T1 (Week 1) — Abnormal0
T2 (Week 2) — Normal43
T2 (Week 2) — Abnormal0
T3 (Week 3) — Normal43
T3 (Week 3) — Abnormal0
T4 (Week 4) — Normal43
T4 (Week 4) — Abnormal0
T5 (Week 5) — Normal43
T5 (Week 5) — Abnormal0
T6 (Week 6) — Normal43
T6 (Week 6) — Abnormal0
T7 (Week 7) — Normal41
T7 (Week 7) — Abnormal0
T8 (Week 8) — Normal36
T8 (Week 8) — Abnormal0
T9 (Week 9) — Normal33
T9 (Week 9) — Abnormal0
T10 (Week 10) — Normal29
T10 (Week 10) — Abnormal0
T11 (Week 11) — Normal29
T11 (Week 11) — Abnormal0
T12 (Week 12) — Normal27
T12 (Week 12) — Abnormal0
T13 (Week 13) — Normal23
T13 (Week 13) — Abnormal0
T14 (Week 14) — Normal6
T14 (Week 14) — Abnormal0
Other pre-specifiedInjection Site Reaction - Drug Absorption - Site 2

Summary of injection site reaction assessment - drug absorption @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Count of participants · Participants
Injection Site Reaction - Drug Absorption - Site 2
ParticipantsPRO 140 350mg
T1 (Week 1) — Normal43
T1 (Week 1) — Abnormal0
T2 (Week 2) — Normal43
T2 (Week 2) — Abnormal0
T3 (Week 3) — Normal43
T3 (Week 3) — Abnormal0
T4 (Week 4) — Normal43
T4 (Week 4) — Abnormal0
T5 (Week 5) — Normal43
T5 (Week 5) — Abnormal0
T6 (Week 6) — Normal43
T6 (Week 6) — Abnormal0
T7 (Week 7) — Normal41
T7 (Week 7) — Abnormal0
T8 (Week 8) — Normal36
T8 (Week 8) — Abnormal0
T9 (Week 9) — Normal33
T9 (Week 9) — Abnormal0
T10 (Week 10) — Normal29
T10 (Week 10) — Abnormal0
T11 (Week 11) — Normal29
T11 (Week 11) — Abnormal0
T12 (Week 12) — Normal27
T12 (Week 12) — Abnormal0
T13 (Week 13) — Normal23
T13 (Week 13) — Abnormal0
T14 (Week 14) — Normal6
T14 (Week 14) — Abnormal0
Other pre-specifiedInjection Site Reaction - Pain Post Injection - Site 1

Summary of injection site pain assessment (VAS) post injection mean change from baseline. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. Higher score is worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Mean · score on a scale
Injection Site Reaction - Pain Post Injection - Site 1
score on a scalePRO 140 350mg
T1 (Week 1)18.4 ± 16.1
T2 (Week 2)-3.9 ± 8.6
T3 (Week 3)-7.9 ± 11.4
T4 (Week 4)-2.5 ± 14.2
T5 (Week 5)-12.8 ± 13.9
T6 (Week 6)-6.8 ± 16.7
T7 (Week 7)-13.5 ± 13.9
T8 (Week 8)-16.6 ± 14.8
T9 (Week 9)-15.0 ± 14.2
T10 (Week 10)-17.2 ± 12.3
T11 (Week 11)-24.0 ± 18.1
T12 (Week 12)-22.0 ± 18.4
T13 (Week 13)-17.0 ± 15.6
T14 (Week 14)-22.0 ± 19.1
Other pre-specifiedInjection Site Reaction - Pain Post Injection - Site 2

Summary of injection site pain assessment (VAS) post injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. A higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From initiation of PRO 140 monotherapy through week 14
Reported as:
Mean · score on a scale
Injection Site Reaction - Pain Post Injection - Site 2
score on a scalePRO 140 350mg
T1 (Week 1)17.4 ± 15.2
T2 (Week 2)-2.0 ± 14.2
T3 (Week 3)-4.8 ± 11.8
T4 (Week 4)-7.8 ± 12.2
T5 (Week 5)-8.8 ± 15.7
T6 (Week 6)-7.2 ± 17.6
T7 (Week 7)-10.4 ± 14.8
T8 (Week 8)-13.0 ± 15.9
T9 (Week 9)-14.6 ± 16.0
T10 (Week 10)-10.7 ± 9.1
T11 (Week 11)-14.7 ± 13.3
T12 (Week 12)-15.2 ± 14.8
T13 (Week 13)-10.0 ± 10.3
T14 (Week 14)-13.8 ± 18.5
Other pre-specifiedInjection Site Reaction - Pain Pre Injection - Site 1

Summary of injection site pain assessment (VAS) pre injection @ Site 1 Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From week 2 through week 14
Reported as:
Mean · score on a scale
Injection Site Reaction - Pain Pre Injection - Site 1
score on a scalePRO 140 350mg
T2 (Week 2)0.0 ± 0.0
T3 (Week 3)2.8 ± 8.4
T4 (Week 4)1.7 ± 6.6
T5 (Week 5)2.2 ± 4.2
T6 (Week 6)1.6 ± 4.2
T7 (Week 7)1.0 ± 4.0
T8 (Week 8)0.9 ± 3.6
T9 (Week 9)1.6 ± 4.1
T10 (Week 10)1.5 ± 5.9
T11 (Week 11)1.3 ± 4.7
T12 (Week 12)0.5 ± 4.1
T13 (Week 13)0.6 ± 1.3
T14 (Week 14)0.0 ± NA
Other pre-specifiedInjection Site Reaction - Pain Pre Injection - Site 2

Summary of injection site pain assessment (VAS) pre injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.

Time frame:
From week 2 through week 14
Reported as:
Mean · score on a scale
Injection Site Reaction - Pain Pre Injection - Site 2
score on a scalePRO 140 350mg
T2 (Week 2)0.0 ± 0.0
T3 (Week 3)2.4 ± 9.2
T4 (Week 4)4.8 ± 19.9
T5 (Week 5)2.1 ± 7.1
T6 (Week 6)2.0 ± 7.1
T7 (Week 7)0.8 ± 6.9
T8 (Week 8)1.1 ± 6.5
T9 (Week 9)1.9 ± 7.2
T10 (Week 10)1.7 ± 8.5
T11 (Week 11)1.4 ± 7.7
T12 (Week 12)0.1 ± 5.3
T13 (Week 13)0.4 ± 0.8
T14 (Week 14)0.0 ± NA
Other pre-specifiedPro 140 Concentration

Summary of Pro 140 Concentration. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL).

Time frame:
At week 4, week 8, week 12 and viral failure visits
Reported as:
Mean · ng/ml
Pro 140 Concentration
ng/mlPRO 140 350mg
T4 (Week 4)18084 (8152 to 37318)
T8 (Week 8)22010 (6965 to 41624)
T12 (Week 12)26388 (11632 to 74414)
VF (Viral Failure)16258 (8133 to 26396)

Adverse events

Collected over Adverse events were collected for a total of 18 weeks, from treatment visit 1 (Post Rx) to treatment visit T14 (Week 14) and through the follow up period, every 2 week for total of 4 weeks. The duration of follow-up depends on the status of viral load suppression. Subjects who experience Virologic Failure will be discontinued from the treatment phase and be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to <50 copies/mL).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leronlimab0/43 (0%)1/43 (2.3%)7/43 (16.3%)
Most frequent serious events
Most frequent serious events
EventLeronlimab
transient ischemic attackNervous system disorders1/43
Most frequent other events
Most frequent other events
EventLeronlimab
nasopharyngitisInfections and infestations4/43
DiarrhoeaGastrointestinal disorders4/43
nauseaGastrointestinal disorders4/43
FatigueGeneral disorders4/43
Injection site pruritusGeneral disorders4/43
ConstipationGastrointestinal disorders3/43
DizzinessNervous system disorders3/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)PRO 140
Mean53.1 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)PRO 140
Female3
Male40
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PRO 140
Hispanic or Latino9
Not Hispanic or Latino34
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRO 140
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White34
More than one race0
Unknown or Not Reported5
Time since HIV Diagnosis (Years)
Time since HIV Diagnosis (Years)(years)PRO 140
Mean18.8 ± 9.5
08

Study locations

1 site
  • Quest Clinical Research
    San Francisco, California 94115, United States
09

References and documents

Publications

  • Chang XL, Reed JS, Webb GM, Wu HL, Le J, Bateman KB, Greene JM, Pessoa C, Waytashek C, Weber WC, Hwang J, Fischer M, Moats C, Shiel O, Bochart RM, Crank H, Siess D, Giobbi T, Torgerson J, Agnor R, Gao L, Dhody K, Lalezari JP, Bandar IS, Carnate AM, Pang AS, Corley MJ, Kelly S, Pourhassan N, Smedley J, Bimber BN, Hansen SG, Ndhlovu LC, Sacha JB. Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species. PLoS Pathog. 2022 Mar 31;18(3):e1010396. doi: 10.1371/journal.ppat.1010396. eCollection 2022 Mar. PubMed 35358290 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Feb 2015, 9 months.

Results were first posted in Apr 2023, 8 years 2 months after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 9 months is below that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 26, 2014
StartActual
Apr 16, 2014
Primary completionActual
Feb 2, 2015
CompletionActual
Feb 2, 2015
Results first posted
Apr 14, 2023
Last update
Apr 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02175680
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Apr 16, 2014
Primary completion
Feb 2, 2015
Completion
Feb 2, 2015
Results posted
Apr 14, 2023
Last update
Apr 14, 2023

Study contacts

Jacob Lalezari, MD
principal investigator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion